Investor.lundbeck.com

Investor Lundbeck. Lundbeck A/S's business for stockholders, potential investors, and financial analysts.

Today's Investor.lundbeck.com headlines: Observe fresh posts and updates on Investor Lundbeck. This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Investor.lundbeck.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Investor Lundbeck

Subscribe to related news

The Lundbeck Emails [Citalopram Birth Defects]
via fiddaman.blogspot

Two weeks ago Cheryl Buchanan wrote a guest post for this blog entitled 'Citalopram Birth Defects'. Cheryl told how, after just 12 weeks, she was informed that the child she was carrying had a series of anomalies. Cheryl wrote: The most severe of which...
Lundbeck: Remedying IP Overprotection through Competition Law Enforcement in the Pharma Sector
via europeanlawblog

By Konstantinos Sidiropoulos Introduction On 8 September 2016, the General Court (‘GC’) handed down a seminal judgment for the pharmaceutical sector in the Lundbeck case. The judgment is of particular importance, because it is the very first ruling...
Lundbeck Epilepsy Research Featured in Report on Neurological Disorders
via noahsarkconsulting.blogspot

Published: Thursday, Aug. 29, 2013 / Updated: Thursday, Aug. 29, 2013 02:40 PM Lundbeck’s epilepsy commitment includes long-term research, education and advocacy investment DEERFIELD, Ill. -- Lundbeck’s epilepsy research efforts...
Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for...
via tpna

Osaka, Japan and Copenhagen, Denmark – October 1, 2012 –Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA...
FDA Accepts Takeda and Lundbeck’s Submission of the New Drug Application for Vortioxetine for the Treatment of Major Dep...
via tap

Deerfield, Ill. – December 12, 2012 –Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New...

Investor.lundbeck.com popular pages

Financial Overview - H. Lundbeck A/S

The Investor Relations website contains information about H. Lundbeck A/S business for stockholders, potential investors, and financial analysts.
New study showed improvement in cognitive performance in adult patients treated with Brintellix® (vortioxetine) for acute episodes

Valby, Copenhagen, 2013-12-10 23:30 CET (GLOBE NEWSWIRE) -- Outcome from the FOCUS study was presented at ACNP and Brintellix 10 mg and 20...

Investor Relations - H. Lundbeck A/S

Global contacts We operate in more than 57 countries around the world. If your country is not on the list, please refer to our global contacts.